Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The skeleton is constantly being remodelled by the breakdown of old bone by cells called osteoclasts and the formation of new bone by cells called osteoblasts. This coordinated activity is essential for maintaining healthy bone. However, excessive osteoclast activity leads to bone destruction in skeletal diseases such as osteoporosis, rheumatoid arthritis and cancer metastases in bone. A family of signaling enzymes known as phosphatidylinositol 3-kinases (PI3Ks) control diverse cell functions but, up until now, little was known about the function of specific PI3K isoforms in osteoclasts.
A paper published in the Journal of Biological Chemistry announces the characterization of a new potent and selective PI3Kdelta inhibitor, GS-9820. The discovery was made by members of Western University's Bone and Joint Initiative with collaborators from Nihon University, the University of Calgary and Gilead Sciences, Inc.
Graduate student Ryan Shugg, working under the supervision of Stephen Sims, PhD, and Jeff Dixon, PhD, of Western's Department of Physiology and Pharmacology, used a panel of isoform-selective inhibitors and found that one isoform in particular, PI3Kdelta, regulates osteoclast shape and resorptive activity.
Sims says, "These findings suggest that selective inhibition of PI3K isoforms offers a new approach for the treatment of inflammatory bone diseases and skeletal metastases."
The studies were carried out by an interdisciplinary team, which included undergraduate student Ashley Thomson, visiting professor Natsuko Tanabe, research scientist Alexey Pereverzev, investigator Frank Jirik at the McCaig Institute for Bone and Joint Health (University of Calgary), along with researchers Adam Kashishian, Bart Steiner, Kamal Puri, and Brian Lannutti from Gilead Sciences.
"Collaboration among researchers at Gilead Sciences, Western, Calgary and Nihon Universities was critical for accessing and testing this novel inhibitor" says Sims. "Such partnerships are essential for translating progress in fundamental cell biology into therapeutic advances."
These studies were funded in part by grants from the Canadian Institutes of Health Research (CIHR) and the Alberta Cancer Foundation. Shugg is the recipient of a Frederick Banting and Charles Best Canada Graduate Scholarship from the CIHR.
Effects of Isoform-Selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts: ACTIONS ON CYTOSKELETAL ORGANIZATION, SURVIVAL AND RESORPTION. J Biol Chem. 2013 Oct 16. [Epub ahead of print]
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Arthritis / Rheumatology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
University of Western Ontario. "Bone destruction in diseases such as arthritis and cancer: new target identified for prevention." Medical News Today. MediLexicon, Intl., 6 Dec. 2013. Web.
10 Mar. 2014. <http://www.medicalnewstoday.com/releases/269745>
University of Western Ontario. (2013, December 6). "Bone destruction in diseases such as arthritis and cancer: new target identified for prevention." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269745.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.